Blood
Articles in this Issue
Flow cytometry–based evaluation of TRBC1/TRBC2 facilitates identification of indolent T-lymphoblastic proliferations
Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what’s next?
Abstract The use of posttransplant cyclophosphamide was initially pioneered as a means of permitting haploidentical transplantation across HLA barriers. This approach has now becom...
The XPO7-NPAT axis represents key vulnerabilities in <i>TP53</i> -mutated acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) with TP53 mutations is almost universally refractory to chemotherapy, molecular-targeted therapies, and hematopoietic stem cell transplantatio...
Human missense variants in <i>F3</i> impair the initiation of blood coagulation
Abstract Tissue factor (TF), encoded by F3, binds factor VII (FVII)/activated factor VII (FVIIa) to initiate blood coagulation. Because standard clinical assays do not measure endo...
Switching and Sniffing around the β-globin cluster
Inclusion as innovation: broadening trial criteria in AML
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials
Abstract Clinical trial eligibility criteria select a target population and reduce anticipated risks for participants but may unnecessarily limit participation both overall and dif...
Highly discriminative globin gene activation by the noncanonical BAF chromatin remodeling complex
Abstract The regulation of the switch from fetal (HBG) to adult (HBB and HBD) β-globin gene expression has served as a paradigm for clinically relevant developmental transcriptiona...
The first clotting factor is also the last
Clonal cacophony of AML relapse
<i>TP53</i> loss traps AML in XPO7-NPAT nuclear transport fraud
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy
Abstract Acquired resistance to targeted, nonintensive therapies is common in myeloid malignancies. However, the kinetics of selection, the hematopoietic cell compartments in which...
Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term study. <i>Blood.</i> 2025;146(suppl 1):1847.
PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism
Abstract We previously reported a chemogenomics screen that unexpectedly identified phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as a vulnerable target in multiple myeloma (...